Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base.

PURPOSE/OBJECTIVES - The addition of whole pelvic (WP) compared with prostate-only (PO) radiation therapy (RT) for clinically node-negative prostate cancer remains controversial. The purpose of our study was to evaluate the survival benefit of adding WPRT versus PO-RT for high-risk, node-negative prostate cancer, using the National Cancer Data Base (NCDB).

METHODS AND MATERIALS - Patients with high-risk prostate cancer treated from 2004 to 2006, with available data for RT volume, coded as prostate and pelvis (WPRT) or prostate alone (PO-RT) were included. Multivariate analysis (MVA) and propensity-score matched analysis (PSM) were performed. Recursive partitioning analysis (RPA) based on overall survival (OS) using Gleason score (GS), T stage, and pretreatment prostate-specific antigen (PSA) was also conducted.

RESULTS - A total of 14,817 patients were included: 7606 (51. 3%) received WPRT, and 7211 (48. 7%) received PO-RT. The median follow-up time was 81 months (range, 2-122 months). Under MVA, the addition of WPRT for high-risk patients had no OS benefit compared with PO-RT (HR 1. 05; P=. 100). On subset analysis, patients receiving dose-escalated RT also did not benefit from WPRT (HR 1. 01; P=. 908). PSM confirmed no survival benefit with the addition of WPRT for high-risk patients (HR 1. 05; P=. 141). In addition, RPA was unable to demonstrate a survival benefit of WPRT for any subset. Other prognostic factors for inferior OS under MVA included older age (HR 1. 25; P

CONCLUSION - In the largest reported analysis of WPRT for patients with high-risk prostate cancer treated in the dose-escalated era, the addition of WPRT demonstrated no survival advantage compared with PO-RT.

International journal of radiation oncology, biology, physics. 2015 Sep 18 [Epub]

Arya Amini, Bernard L Jones, Norman Yeh, Chad G Rusthoven, Hirotatsu Armstrong, Brian D Kavanagh

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado. , Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado. , Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado. , Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado. , Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado. , Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado. 

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe